Insulet's Omnipod 5 drives a Q1 beat and raised 2026 outlook as upgrades and global rollout expand access - while correction costs loom.

New 100 mg/dL Target Glucose setting offers more customization and tighter glucose management. Enhanced algorithm helps users remain in Automated Mode to improve the user experience. Most requested ...

(RTTNews) - Insulet (PODD) announced it has received FDA 510(k) clearance for significant enhancements to the Omnipod 5 Automated Insulin Delivery System. The new 100 mg/dL Target Glucose expands ...

Insulet Corporation PODD recently received FDA 510(k) clearance for significant enhancements to the Omnipod 5 Automated Insulin Delivery System. These updates to the Omnipod 5 algorithm set a new ...

Insulet Corp. received FDA clearance for its Omnipod 5 closed-loop automated insulin delivery (AID) system for patients aged six and older who have type 1 diabetes on Friday, Jan. 28, making it the ...

Patients with type 1 diabetes (T1D) who used the Omnipod 5 Automated Insulin Delivery (AID) System saw significant improvements in psychosocial outcomes, including diabetes distress and hypoglycemic ...

Insulet (Nasdaq:PODD) today announced a voluntary medical device correction for specific lots of its Omnipod 5, Dash and Eros ...

The US Food and Drug Administration (FDA) has cleared the Omnipod 5 Automated Insulin Delivery System (Insulet Corporation), the third semi-automated closed-loop insulin delivery system in the United ...

2022 is the year of the Omnipod 5 for Insulet. The year kicked off with FDA clearance for the latest generation of the insulin pump—which is tubeless, fully wearable and can be completely controlled ...